Most US neurologists treating patients with multiple sclerosis receive industry payments, with higher payments linked to higher prescribing of that company’s drugs, new research shows.

Multiple sclerosis (MS) has long been regarded as a disease with different subtypes such as "relapsing" or "progressive." An international study, published on August 20, 2025, in Nature Medicine under ...

Scientific study conducted in collaboration with the National Multiple Sclerosis Society Abu Dhabi: In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to ...

From isolation to community: How UAE's MS support network grows MS is a lifelong neurological condition in which the immune system mistakenly attacks myelin—the protective sheath that covers nerve ...

In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has announced the approval of “Tolebrutinib” as ...

The UAE has approved Tolebrutinib, the world’s first oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS). Developed to slow disability progression without relying on ...

Nearly 80% of U.S. neurologists prescribing drugs for multiple sclerosis (MS) have received at least one pharma industry payment, with higher-volume prescribers more likely to be beneficiaries, finds ...

Although multiple sclerosis (MS) is often accompanied by a number of challenging symptoms, moving your body can help alleviate the side effects of this condition. "Multiple sclerosis can manifest a ...

Jan Janisch-Hanzlik, Dr. Matthew Lunning and Dr. Rana Zabad discuss new multiple sclerosis therapy during a press conference at the Buffett Cancer Center in Omaha on Tuesday, Aug. 5, 2025. When the ...

In a global first, the Emirates Drug Establishment (EDE) has approved Tolebrutinib, the only oral treatment specifically developed to slow disability progression in adults with non-relapsing secondary ...